The increase in fetal hemoglobin (HbF) in response to hydroxyurea (HU) varies among patients with sickle cell anemia. Twenty-nine candidate genes within loci previously reported to be linked to HbF level (6q22.3-q23.2, 8q11-q12 and Xp22.2-p22.3), involved in metabolism of HU and related to erythroid progenitor proliferation were studied in 137 sickle cell anemia patients treated with HU. Three-hundred and twenty tagging single nucleotide polymorphisms (SNPs) for genotyping were selected based on HapMap data. Multiple linear regression and the nonlinear regression Random Forest method were used to investigate the association between SNPs and the change in HbF level after 2 years of treatment with HU. Both methods revealed that SNPs in genes within the 6q22.3-23.2 and 8q11-q12 linkage peaks, and also the ARG2, FLT1, HAO2 and NOS1 genes were associated with the HbF response to HU. Polymorphisms in genes regulating HbF expression, HU metabolism and erythroid progenitor proliferation might modulate the patient response to HU.
Introduction
Fetal hemoglobin (HbF) inhibits the polymerization of sickle hemoglobin (HbS). 1 As many of the complications of sickle cell anemia (homozygosity for HBB, glu6val), like osteonecrosis, acute chest syndrome and painful episode, are associated with the level of HbF, and, HbF is inversely associated with mortality, investigators have assiduously sought pharmacological means of increasing HbF production. [2] [3] [4] [5] [6] Hydroxyurea (HU), a ribonucleotide reductase inhibitor, is one drug that increases HbF concentration in patients with sickle cell anemia [7] [8] [9] [10] and it is the sole FDA-approved agent for treating sickle cell anemia. Most, but not all patients respond to HU treatment with an increase in HbF, but as with the baseline HbF concentration, which varies widely among patients, the magnitude of the HbF response to HU is also variable. [10] [11] [12] [13] The regulation of HbF level might be a complex genetic trait governed by genetic elements linked to the b-globin gene-like cluster and quantitative trait loci (QTL) present on chromosomes 6, 8 and on the X-chromosome; other regulatory loci are also likely to exist and epigenetic and cellular factors could also have regulatory roles. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] It is possible that these and other regulatory elements also modulate the HbF response to HU. Accordingly, we hypothesized that single nucleotide polymorphisms (SNPs) in candidate genes or QTL with putative roles in the regulation of HbF production might modulate the HbF response to treatment with HU. We therefore studied the association of SNPs in these loci with response to HU in patients who participated in the Multicenter Study of Hydroxyurea (MSH), a trial designed to evaluate the efficacy of this drug in sickle cell anemia.
Results
The distribution of HbF for 137 patients enrolled in this study is shown as Figure 1 . The change of HbF after HU treatment did not follow a normal distribution and resembled a bimodal distribution with a large portion of people with minor or no change (mean ¼ 0) and a small portion of people with extreme change (mean 440). This distribution suggested that categorizing these data, like dividing subjects into quartiles by the HbF change, and comparing patients in lowest quartile group vs those patients in the highest quartile of change, might be an alternative approach for analyzing these data. However, considering the relatively small sample size in our study, this approach provides very limited power for detecting genetic associations.
Three-hundred and twenty tagging SNPs in 29 candidate genes (Table 1) were examined in 137 sickle cell anemia patients treated with HU. We considered an SNP to have a significant association with response to HU treatment when the P-value was p0.01, unless there was more than one SNP in a gene showing an association when the P-value for significance was set at 0.05. Tables 2 and 3 present the  statistically significant results of the quantitative trait  analysis for single SNP association with the change of HbF  level after a 2 -year treatment, expressed as percentage of total hemoglobin and as the absolute HbF level, expressed as g/dl, respectively. An analysis was also performed expressing the increment in HbF after HU treatment as F-cells.
Seventeen SNPs were significantly associated with the change in percent HbF (Table 2) . They included two in MAP3K5, five in TOX, two in NOS1, three in FLT1, two in ARG2 and two in NOS2A. The most significant association was observed with SNP rs2182008 (P ¼ 0.003) in FLT1 (Fms-related tyrosine kinase 1), a vascular endothelial growth factor, which is involved in cell proliferation and differentiation. Twenty SNPs were significantly associated with the change of absolute HbF (Table 3) ; a similar pattern of association was observed and the most significant association was in SNP rs10483801 (P ¼ 0.0013) in ARG2 (arginase type II, involved in drug metabolism of HU). Using F-cells as the outcome measure gave similar results (data not shown).
For candidate genes with significant association in multiple SNPs, haplotype associations were explored using Haplo.stats (version 1.2.1) as given in the R library (available at http://cran.us.r-project.org). 28 However, as these SNPs studied here are tagging SNPs and most of them are not in linkage disequilibrium (LD) with each other, we did not find improved association by haplotype analysis in any genes (data not shown).
The results of joint analysis of all the SNPs and covariates (age, sex and the a-and b-globin gene cluster haplotypes) using Random Forest analysis are shown in Figures 2 and 3 . The relative importance of one independent variable (a SNP) is measured by %IncMSE (see Materials and methods for details), and the larger the value of %IncMSE, the higher importance that variable has for correct prediction of HbF response to HU. This analysis revealed that the most important variables for predicting the change of HbF level matched most of the SNPs identified by SNP association analysis. Interestingly, SNPs within ASS (argininosuccinate synthetase) and ARG1 (arginase, liver) were observed to have strong effect on the change of HbF level, which was not detected by single SNP association analysis. This suggests that these two genes might be involved in interaction with other genes to regulate the response to HU treatment.
SNP rs2182008 in FLT1 showed a strong effect on response to HU treatment. This SNP was significantly associated with the change in HbF under a dominant model (P-value ¼ 0.003 for HbF in percentage and 0.002 for HbF in g/dl) and it was also a highly ranked predictor for response to HU from the Random Forest analysis (second for HbF in percentage and third for HbF in g/dl). The A allele of this SNP was associated with increased HbF level after HU treatment; there is no difference between AA and AG genotypes and the increase in HbF in subjects with these genotypes was on average 5.9 times higher than that in subjects with the GG genotype ( Figure 4 ). 
Discussion
HU can increase HbF concentration in most individuals with sickle cell anemia but some patients who take the drug exactly as directed by experienced physicians either fail to respond or have an HbF response that might not be clinically significant. Even among patients with an increase in HbF, the magnitude of this increase varies. [10] [11] [12] [13] The cause of this variability is poorly understood. 11, 12, 29, 30 HbF concentration in blood is determined by interactions among chromosome remodeling activities, transcription factors, genes modulating erythropoiesis, genetic elements linked to the b-globin gene cluster, the kinetics of erythroid cell differentiation and differential red cell survival (for reviews see Bank 31 and Stamatoyannopoulos 32 ). This complex regulatory environment provides ample opportunity for genetic modulation of HbF production. Because of evidence suggesting that heterogeneity in genetic elements modulate HbF baseline concentration, we reasoned that similar heterogeneity might account for the varied response in HbF among sickle cell anemia patients treated with HU.
We found statistically significant associations of the HbF response to HU with multiple SNPs in several genes. TOX (thymus high-mobility group box protein) is located within the 8q11-q12 linkage peak that Garner et al., 16, 33 found to interact with the À158 CT 5' G g-globin gene SNP and that might also effect the g-to b-globin gene switch. A member of the high-mobility group (HMG) box protein family, TOX contains a single HMG box motif and binds DNA in a sequence-specific manner. All HMG box proteins are able to induce a sharp bend in DNA. Multiple SNPs in PDE7B (phosphodiesterase 7B) within 6q22-q23 QTL were also associated with the HbF response to HU. SNPs in this gene were previously reported to be associated with baseline HbF level in patients with sickle cell anemia. 21 Nitric oxide (NO) binds and activates sGC, which increases cGMP production. cGMP interacts with transcription factors increasing the expression of the g-globin SNPs, hydroxyurea and HbF in sickle cell anemia Q Ma et al genes. 34 ASS (argininosuccinate synthetase) is an enzyme that catalyzes the penultimate step of the arginine biosynthetic pathway. Arginine is the substrate for the NO synthases. SNPs in ASS gene were strong predictors for HbF response to HU. Significant associations were also found with SNPs in ARG2 and ARG1, genes coding for enzymes SNPs, hydroxyurea and HbF in sickle cell anemia Q Ma et al that hydrolyze arginine to ornithine. SNPs in NOS1 (12q24.2-q24.31, neuronal NO synthase) and NOS2A, an NO synthase expressed in liver, were also associated with HbF response to HU. FLT1 (vascular endothelial growth factor (VEGF)/vascular permeability factor receptor) is a receptor for VEGF. SNP rs2182008 in this gene was found to be strongly associated with the HbF response to HU. This gene has tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation. 35 Most SNPs associated with HbF response to HU treatment were in either untranslated portions of the genes or in introns. Most likely, the associations we found are in LD with the actual functionally important elements. Although most associations have biologically plausible mechanisms by which they might influence the expression of the g-globin genes or the concentration of HbF, our studies are hypothesis generating rather than mechanistic, and we were unable to do functional studies because of the nature of our study samples. Nevertheless, these SNPs were associated with HbF concentration, for example, the increase of HbF in subjects carrying A allele of SNP rs2182008 was almost six times higher than that in subjects with GG genotype.
To identify genetic factors regulating the expression of HbF in sickle cell anemia at baseline and in the absence of treatment with HU, we studied a sample of 327 subjects and an independent group of 987 subjects. We replicated in part our previous work 21 using this expanded sample of patients and denser SNP coverage, by finding multiple tagging SNPs in genes abutting the 6q22.3-q23.2 QTL. We also found a significant association of HbF with SNPs in TOX and within EGFL6, GPM6B and FIGF in the Xp22.2-p22.3 QTL (unpublished data).
According to the common disease-common variant hypothesis, many of the genetic variants causing complex diseases or phenotypes are expected to have only a small effect on disease outcome. 36 The power to obtain SNPs, hydroxyurea and HbF in sickle cell anemia Q Ma et al typical thresholds of P-value significance after applying multiple testing corrections is limited for such markers, because significance is a function of sample size, allele frequency and effect size. Considering our relatively small sample size, which nevertheless constitutes the largest number of patients with sickle cell anemia taking HU under controlled conditions, we validated our findings by using a different analytical method but did not apply multiple testing corrections for reporting our results. Also, as we selected haplotype tagging SNPs that tag different LD blocks and almost all our associations are with more than a single SNP in a gene, it is unlikely that the result with one SNP merely reflects the same association signal with other SNPs. Therefore, out of the 320 SNPs tested, it is less likely that multiple hits with SNPs in the same gene is a chance event. Further replication with fewer candidate genes and denser SNP coverage may be a more practical way to reduce false discovery and confirm our findings.
Materials and methods
Patients DNA samples and laboratory data from adult AfricanAmericans with sickle cell anemia who participated in the MSH were analyzed. This was a randomized, placebocontrolled, double-blind trial designed to test whether HU could reduce the number of vasoocclusive events in adults with moderate to severe sickle cell anemia. 37 HU was given daily, in a single dose starting at 15 mg/kg, and increased by 5 mg/kg every 12 weeks up to a maximum-tolerated dose of 35 mg/kg, unless toxicity developed. When toxicity occurred, treatment was stopped until blood counts recovered. HU was then resumed at a dose 2.5 mg/kg lower than the toxic dose. The MSH enrolled 299 patients, of which 152 were randomly assigned to HU. The minimum length of follow-up evaluation for patients with HbF measured at the end of the study was 21 months (maximum, 38 months; mean, 28). DNA samples were available and HbF was measured in 137 of the 152 patients randomized to receive HU. Although pill counts and measurements of serum HU levels were used to assess compliance with treatment, the rapid clearance of HU from the circulation prevented us from knowing with certainty if a patient took all of the medication prescribed. The studies reported here were approved by the IRB of Boston Medical Center.
Laboratory studies
HbF was measured by alkali denaturation at least twice pretreatment and twice post-treatment. 10 The laboratory methods used to define the hemoglobin phenotype and the haplotypes of the b-like and a -globin gene cluster were described previously. 11, 38, 39 SNP selection and genotyping The selection of genes was based on previously reported linkage peaks (6q22-q23, 8q11-q12 and Xp22.2-p22. 3) 16, 19, 40 genes involved in metabolism of HU and genes related to erythroid progenitor proliferation. Thirty-three candidate genes were chosen in our study, and 320 tagging SNPs were selected based on genotype data from the HapMap project (Phase I, Yoruba sample) 41 using Haploview (v3.2) 42 (Table 1) . Genotyping was carried out using a custom 384 multiplex design using an Illumina platform. For quality control purposes, about 3% of the DNA samples were re-genotyped, and Hardy-Weinberg equilibrium was assessed for each SNP. Hardy-Weinberg equilibrium was determined before analysis and was performed for quality control purposes rather than to evaluate if the genotypes met Mendelian expectation because all members of our study population have sickle cell disease. [43] [44] [45] [46] [47] [48] SNPs that had more than 25% missing genotypes or less than 5% minor allele frequency were not considered in the analysis. This resulted in 280 SNPs being tested for association.
Statistical analysis
Single SNP association was investigated via multiple linear regression analysis (SAS v9.1) with simultaneous adjustment for age, sex and the a-and b-globin gene cluster haplotypes. Three genetic models (codominant, dominant and recessive) governing modulation of response to HU treatment were tested. In the codominant system, an allele causes the homozygous form to look different from the wild-type and the heterozygous form (all three look different from each other). In dominant transmission, an allele causes the homozygous and the heterozygous forms to look the same as each other, but different from the wild type. In a recessive model, an allele affects the phenotype if it is present in the homozygous state only. One subject exceeding the top third standard deviation of all the values of the change in HbF levels was omitted from the analysis to prevent the extreme values from biasing the results.
We used the nonlinear regression Random Forest method to identify additional predictors of response to HU treatment and to validate our results from single SNP association. 49 Random Forest consists of a collection of regression trees, each regression tree itself being a regression function. Each of these trees predicts a real value by querying a set number of variables and instances within the regression model. Each regression tree is thus trained on a different bootstrap sample of both training instances and features. The Random Forest then averages the predictions made by the trees in the forest to produce the final output. Random Forest is a variance reduction technique and has provable properties with regard to resisting over fitting. Additionally, Random Forest is very efficient to train and test, and has built-in mechanisms for estimating test error and confidence in each prediction made. This procedure is nonparametric, not model based, and identifies those independent variables that best segregate subgroups as important predictors and identifies interactions among independent variables. The relative importance of the independent variables (e.g. SNPs in our case) is defined as follows. The mean of squared residuals (MSE) is computed on the out-of-bag data for each tree, and then the same is computed after permuting a variable. The differences are averaged over all trees and normalized by the standard error, and this calculation is repeated for each independent variable. A large difference in MSE (%IncMSE) indicates that the independent variable is important for correct prediction, whereas a small difference indicates that the independent variable is less important for correct prediction. Relative importance provides a measure by which predictors can be ranked with respect to each other. Our analyses were performed using the Random Forest (v 4.5-16) package as given in the R library (available at http://cran.us.r-project.org), except that, as the number of trees to be grown in the SNPs, hydroxyurea and HbF in sickle cell anemia Q Ma et al forest was set at 2500, we used default parameters of this program.
